WCG Buys E-clinical Software and Translation Provider VeraSci
US-based clinical research provider WCG acquires VeraSci, a provider of e-clinical software and translation, for USD 330m; plans Nasdaq IPO.
US-based clinical research provider WCG acquires VeraSci, a provider of e-clinical software and translation, for USD 330m; plans Nasdaq IPO.
Slator’s 2019 report on the clinical life sciences translation industry, analysis of the competitive landscape and actionable insights from major buyers of pharmaceutical translation.
The EU is expected to enact a sweeping overhaul of its regulatory framework for medical devices in early 2017, which includes changes to requirements for multilingual documentation. Brexit also adds to uncertainty.
Two barriers to entry face US medical device companies that want in to China, and the Chinese government has begun to close loopholes; a look at opportunities and expert insights on the medical device market in the world's most populous nation.
Since the start of 2015, China has launched 22 new policies aimed at reforming the regulatory framework for local and international pharma and medical device companies. Sponsored by Lionbridge, Slator’s Shanghai roundtable provided participants a timely update on how policy impacts day-to-day operations
Medical device manufacturers need to keep tight control over content to comply with regulators while staying nimble to get their message across to customers: an exclusive look behind the scenes at how translation is managed at MED-EL, an Austrian manufacturer of hearing implants.
CROs have become some of the language industry’s most coveted and profitable clients with accounts potentially exceeding 5mn USD or more in annual billings.
Your information will never be shared with third parties. No Spam.